Cancer Drugs Repurposed as Senolytic Therapies Show Promise for Aging
Review reveals how anti-cancer drugs are being repurposed to eliminate senescent cells, opening new pathways for longevity treatments.
Summary
This comprehensive review examines how senescent cells and cancer cells share similar biological characteristics, called meta-hallmarks, including resistance to cell death, altered metabolism, and immune evasion. Researchers found that many effective senolytic drugs—which selectively eliminate aging senescent cells—are actually repurposed cancer treatments. Since 2015, when the first senolytic drugs dasatinib and quercetin were discovered, most new senolytics have been adapted from existing anti-tumor therapies. This connection suggests a promising strategy for developing new anti-aging treatments by leveraging the shared vulnerabilities between senescent and cancer cells.
Detailed Summary
This review provides a comprehensive analysis of the striking similarities between senescent cells and cancer cells, revealing why many successful senolytic drugs are repurposed cancer treatments. The authors systematically examined what they term 'meta-hallmarks'—shared characteristics between these cell types including apoptosis resistance, metabolic reprogramming, secretory phenotypes, epigenetic modifications, and immune surveillance evasion.
The field of senolytic drug discovery began in 2015 with dasatinib and quercetin, discovered through bioinformatics-informed approaches. Since then, researchers have identified numerous senolytic agents, with most being repurposed from anti-tumor therapeutics. Examples include panobinostat (an FDA-approved HDAC inhibitor for multiple myeloma) that eliminates chemotherapy-induced senescent cells, and ABT737 (a Bcl-2 family inhibitor) that clears senescent macrophages and neuronal cells.
Clinical applications show remarkable breadth. In cardiovascular disease, ABT263 reduced pro-inflammatory molecules and matrix-degrading proteases in ischemia-reperfusion injury. For skeletal health, dasatinib plus quercetin improved age-related disc degeneration and postmenopausal osteoporosis. Neurological applications include phase I trials showing good tolerability for Alzheimer's disease treatment. In cancer therapy, sequential treatment strategies use conventional therapies to induce senescence followed by senolytics to eliminate persistent senescent tumor cells.
The review categorizes existing senolytic drugs based on their mechanisms targeting shared meta-hallmarks. First-generation drugs primarily targeted senescent cell anti-apoptotic pathways, while second-generation drugs employ diverse mechanisms including autophagy regulation, metabolic disruption, and immune modulation. This systematic approach has accelerated discovery through high-throughput screening and computational methods.
The clinical translation shows promise across multiple aging-related diseases, from cardiovascular and skeletal disorders to neurodegeneration and cancer. However, the field remains in early stages, requiring deeper mechanistic understanding and more systematic research to fully realize therapeutic potential.
Key Findings
- Most senolytic drugs discovered since 2015 are repurposed from existing anti-tumor therapeutics, leveraging shared vulnerabilities
- Dasatinib plus quercetin combination showed good tolerability and biomarker modulation in phase I Alzheimer's disease trials
- ABT263 selectively decreased IL-6 and senescent vascular smooth muscle cells, substantially reducing atherogenesis in preclinical models
- Sequential senolytic therapy after conventional cancer treatment enhanced therapeutic efficacy by eliminating persistent senescent tumor cells
- UBX0101 rescued protein oxidative stress in knee joints, demonstrating potential for osteoarthritis treatment in clinical trials
- ARV-825 inhibited hepatocellular carcinoma progression through autophagy-mediated senolysis mechanisms
- Fisetin alleviated IL-1β-stimulated chondrocyte inflammation and extracellular matrix degradation in osteoarthritis models
Methodology
This is a comprehensive literature review analyzing the meta-hallmarks shared between senescent and cancer cells. The authors systematically categorized existing senolytic drugs based on their mechanisms of action and therapeutic targets. They reviewed clinical trial data, preclinical studies, and drug discovery approaches from 2015 to present, focusing on repurposed anti-cancer agents and their senolytic properties.
Study Limitations
As a review article, this work synthesizes existing research rather than presenting new experimental data. The authors note that the senolytic field is still in its infancy, requiring deeper mechanistic understanding and more systematic research. Many promising senolytic drugs remain in preclinical or early clinical stages, with long-term safety and efficacy data still pending.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.